🇺🇸

Index Intelligence

· daily

S&P 500 Consumer Discretionary Sector SEC Filings — October 22, 2026

Across the four filings, the Consumer Discretionary stream shows a split picture: top-line pressure at Las Vegas Sands (Q3 revenue down roughly 3% YoY to $3.22B, net income down about 28%) and Tesla's core automotive economics (Q3 revenue flat at -0.2%, operating income down 55.8%, net income attributable to common down 42.7%), offset by Tesla's nine-month revenue growth of 12.5% to $78.7B. Margin compression is the dominant theme: LVS consolidated adjusted property EBITDA fell from $1.34B to $1.12B, and Tesla's R&D spend rose 69.4% to $2.76B, crowding out operating income. Capital returns remain a strength for LVS, which repurchased $950M of stock in the quarter and lifted its 2027 dividend 20% to $1.44/share, while rising borrowing costs (4.7% vs 4.5%) and a higher effective tax rate (22.5% vs 15.6%) weigh on earnings. eBay's 8-K signals a restructuring with workforce reductions and expense savings, though the excerpt provides no quantified costs or headcount figures. Starbucks' filing is a routine, small 10b5-1 sale by its CEO-level insider and carries limited signal. Overall, the market implication is that profitability, not demand, is the central debate for these names, with restructuring and capital allocation decisions shaping the near-term narrative.

2 high priority 2 medium 4 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — October 22, 2026

This digest covers a single pre-analyzed filing in the USA S&P 500 Healthcare stream: a Form 4 for Vertex Pharmaceuticals, in which director Daniel J. Brennan received a routine equity award of 795 common shares at $503.47 (about $400K) and now holds 795 shares following the transaction. The filing carries neutral sentiment and a materiality score of 5/10. No period-over-period financial comparisons, forward-looking guidance, M&A details, or capital allocation changes were included in the enriched data, so portfolio-level trend analysis across companies is not possible from this filing alone. The only insider activity is a compensation-related grant, which signals neither conviction nor concern on its own. The primary takeaway is that no actionable investment signal emerges from this single filing; the stream would benefit from additional filings to establish sector-level patterns.

1 high priority 1 total filings
· daily

S&P 500 Technology Sector SEC Filings — October 21, 2026

The eight filings dated 2026-10-21 are almost entirely Form 4 insider transaction reports from S&P 500 technology constituents (Analog Devices, Qualcomm, CrowdStrike), so the digest is dominated by insider activity rather than period-over-period financial results. Qualcomm accounts for six of the eight filings, all recording restricted stock unit awards to its executive officers, which reads as routine compensation grants rather than a directional signal. The two open-market sales came from Analog Devices' CFO (a ~$584K sale under a Rule 10b5-1 plan, retaining ~48,177 shares) and CrowdStrike's CEO George Kurtz (multiple sales totaling roughly $2.0M across 13 transactions, all under a 10b5-1 plan, retaining ~7.42M shares). Because the enriched data carries no revenue, margin, guidance, capital allocation, or M&A figures for these filings, the period-comparison and forward-looking analysis requested cannot be substantiated; conclusions here are limited to insider behavior and compensation. Both sales were scheduled under 10b5-1 plans, which weakens any inference of management conviction or concern from the selling alone. Overall the stream reads as low-signal, with the main actionable item being to pull the underlying 10-Q/10-K and earnings materials to test the sector themes that this filing set cannot support.

8 high priority 8 total filings
· daily

Nasdaq 100 Stocks SEC Filings — October 21, 2026

Across the 10 in-scope NASDAQ-100 filings for 2026-10-21, the dominant pattern is strong top-line momentum colliding with earnings-quality noise: Intuitive Surgical (revenue +21.7% YoY to $3,048.7M) and Netflix (revenue +11.9% YoY to $12,874M, operating income +37.3%) show healthy growth, yet Intuitive's $450M antitrust settlement cut Q3 operating income 22.0% and net income 25.8%, while Tesla's operating income fell 56% YoY to $718M despite flat revenue of $28,046M. Shareholder returns are accelerating and increasingly debt- or cash-funded: Intuitive's share repurchases rose 111% and Netflix repurchased $4,797M in the quarter (up from $1,857M) while its cash declined to $8,194M and short-term debt rose to $2,475M. Tesla's services and other revenue grew about 33% to $4,605M and energy storage orders reached record levels, offsetting a 16% decline in energy generation revenue. Insider activity is light and largely routine: Qualcomm's executive team received broad RSU grants (CEO 65,704 units) with no open-market buying, while Analog Devices' CFO and Meta's COO sold modestly under 10b5-1 plans, which reads as neutral-to-cautious rather than alarming. The portfolio-level read is that growth remains intact but margin and cash-flow quality, not demand, is the key debate into the next catalysts.

11 high priority 11 total filings
· daily

S&P 500 Financials Sector SEC Filings — October 21, 2026

Across the five filings dated 2026-10-21, the S&P 500 Financials stream is dominated by Q3 2026 earnings from two large financial institutions: Northern Trust and CME Group. Northern Trust's headline EPS of $3.40 rose 40% YoY, but sequential declines of 19% in net income and 20% in EPS reflect the non-recurrence of a $525.4M Visa Exchange Offer gain in Q2; excluding notable items, revenue grew 11% YoY with pretax income up 21%, indicating underlying operating strength. CME Group delivered the cleaner print, with revenue up 13.0% YoY to $1.74B, operating income up 17.4%, and record Q3 average daily volume of 29.4M contracts plus record market data revenue of $243M (up 20%), though an 8.4% YoY decline in investment income to $1.42B tempered bottom-line momentum. Exchange and custody franchises are therefore showing volume- and data-driven growth, while balance-sheet-sensitive income streams are softening. Governance activity at Bank of America (two new directors with industrial and audit/AI-investment backgrounds) and routine insider equity transactions at AIG and Northern Trust carry limited financial signal. Overall the stream reads as operationally resilient with mixed quality of earnings, and the key sequential decline in Northern Trust is a one-time comparison effect rather than a deterioration in core economics.

3 high priority 2 medium 5 total filings
· daily

S&P 500 Energy Sector SEC Filings — October 21, 2026

This digest covers a single pre-analyzed SEC filing from the S&P 500 Energy stream, a Form 4-style insider transaction report from Chevron Corp (CVX). The sole filing shows a Chief Legal Officer, Pate R. Hewitt, executing six transactions, including option/conversion exercises at $132.69 and sales at roughly $225-227 per share, with aggregate sales of about $9.2 million and a stated holding of 8,791 shares after the trades. The trades were reported as executed under a Rule 10b5-1 pre-arranged plan, which weakens the signal value of the selling, since such plans are set in advance and are not discretionary timing decisions. The filing's enriched data does not include period-over-period financial comparisons, forward-looking guidance, capital allocation changes, or valuation metrics, so portfolio-level trend analysis across the energy sector is not possible from this input alone. The implication is that the stream's coverage for this period is too thin to support sector-level conclusions, and the material takeaway is limited to an insider-selling event at a large integrated energy major with a materiality score of 8/10. Investors should treat this as a monitoring item rather than a directional call until additional filings with financial and guidance data are available.

1 high priority 1 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — October 21, 2026

Two filings from the S&P 500 Consumer Staples stream were reviewed for the 2026-10-21 window: a Philip Morris International 8-K (Q3 2026 results) and a Hershey Co Form 4 insider filing. Philip Morris delivered a strong top-line and operating story, with net revenues up 5.5% (7.1% organic) to $11.4 billion and record quarterly operating income up 14.1% (10.5% organic), yet adjusted diluted EPS grew only 5.4% to $2.36 while reported EPS fell 4.9% on a non-cash fair value adjustment. Full-year adjusted EPS guidance was narrowed to $8.29-$8.44 (9.9%-11.9% growth), but management flagged a greater likelihood of lower-half operating income growth from geopolitical cost pressure and higher U.S. ZYN commercial investment, so the guidance implies margin pressure in the back half. Within international combustibles, growth of 6.5% was led by 8.9% pricing, but part of it came from a favorable distribution-term restructuring that is not expected to recur at the same level, meaning underlying growth is flattering the headline. Hershey's disclosed activity is limited to a 10% owner trust selling 9 tranches under a Rule 10b5-1 plan, the largest about 7,865 shares at $167.22 (~$1.32M), leaving 536,119 shares held; because the sales are pre-scheduled, they carry weaker conviction signal than discretionary trades. The combined read is that consumer staples franchises with pricing power are still compounding, but management commentary is shifting toward cost and investment headwinds that will test second-half earnings delivery.

1 high priority 1 medium 2 total filings
· daily

S&P 500 Industrials Sector SEC Filings — October 21, 2026

Two filings were reviewed for the S&P 500 Industrials stream on 2026-10-21: CSX Corp's Q3 2026 10-Q and a Form 4 from Paychex. CSX delivered strong headline growth, with Q3 net earnings of $1,052 million (up 51.6% YoY) on revenue of $4,017 million (up 12.0%), though the swing was flattered by the absence of the $164 million goodwill impairment booked in Q3 2025. Underlying cost pressure is visible in fuel expense, up 60.5% in Q3 and 45.5% over nine months, which is the key margin watch item for rail. CSX also reduced long-term debt to $17,102 million from $18,165 million at year-end 2025 while building cash to $1,223 million, signaling improved balance-sheet flexibility alongside continued property investment and buybacks. Paychex's filing is a routine tax-withholding transaction by its CEO at $110.75 (~$45.3K) and carries no directional signal. The stream's sample is thin, so conclusions rest mainly on CSX.

2 high priority 2 total filings
· daily

Dow Jones 30 Stocks SEC Filings — October 21, 2026

Two filings were received for the Dow Jones 30 stream, and both are in scope: Chevron (a DJIA constituent) and Johnson & Johnson (also a DJIA constituent). The Chevron filing is an insider Form 4 showing Chief Legal Officer Pate R. Hewitt exercising options at $132.69 and selling roughly 43,100 shares at about $225-227 (~$9.8M gross across six transactions) under a Rule 10b5-1 plan, leaving 8,791 shares held. The Johnson & Johnson 10-Q shows fiscal Q3 2026 sales up 5.9% YoY to $25,399M and nine-month sales up 7.4% to $74,771M, yet net earnings collapsed to $210M from $5,152M, driven by a $5,780M other expense line swinging from $(478)M of income a year earlier. Gross margin compressed 150 bps to 68.1%, R&D surged 26.7%, and cash fell to $16,910M from $19,709M at year-end 2025. The main portfolio-level theme is a divergence between top-line growth and bottom-line stress: J&J shows revenue momentum undermined by one-off and non-operating charges, while Chevron insider selling is a planned, pre-scheduled disposition rather than a clear conviction signal. Market attention should center on the composition of J&J's other expense and whether impairments and restructuring recur.

2 high priority 2 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — October 21, 2026

Tesla's Q3 2026 supplemental deck (8-K Exhibit 99.1) shows a mixed quarter: total revenue was essentially flat at $28,046M (down 0.2% YoY from $28,095M), but GAAP operating income fell 56% to $718M from $1,624M and GAAP net income attributable to common stockholders fell about 43% to $787M from $1,373M. Operating margin contracted 322 bp YoY even though GAAP gross margin improved 160 bp, signalling that operating expense and investment spending absorbed the gross-margin gains. Cash generation remained positive with operating cash flow of $6,263M and free cash flow of $1,531M, but capital expenditures of $4,732M were heavy, and cash and short-term investments rose to $45,447M. Segment divergence is the central theme: vehicle deliveries fell 2% YoY to 486,532 units and energy generation and storage revenue dropped about 16% to $2,881M from $3,415M, while services and other revenue rose about 33% to a record $4,605M. Market implications hinge on whether record energy storage orders and backlog, 1.74M FSD subscriptions and Robotaxi milestones can offset core automotive stagnation. This is a single-filing digest, so no cross-company sector comparison is possible; the read-through is limited to Tesla's own trajectory.

1 high priority 1 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — October 21, 2026

Across the ten S&P 500 Healthcare filings dated 2026-10-21, the dominant theme is a split between strong top-line and cash-generation momentum in tools, diagnostics and select managed care, and earnings quality stress driven by acquisition financing, impairments, restructuring and one-off charges. Thermo Fisher (revenue +9% YoY, adjusted operating margin 24.5% vs 23.3%) and Danaher (sales +8.3% YoY, net earnings +36%) show healthy underlying growth, but Danaher's core revenue grew only 3.0% and its long-term debt rose to $24,388M from $18,416M after the Masimo close. Abbott's reported Q3 sales rose 14.5%, yet comparable growth was 7.0% and Nutrition nine-month comparable sales fell 2.1%, while Abbott also announced a plan to separate its global nutrition business. Johnson & Johnson's net earnings collapsed to $210M on a $5,780M other expense line, with nine-month net earnings down 49.4%, making the quality of reported earnings the central diligence question. Intuitive Surgical grew revenue 21.7% YoY but absorbed a $450M antitrust settlement charge that cut quarterly operating income 22%, while still repurchasing shares at a pace that drove retained earnings down 35.5%. Managed care (Elevance) showed a benefit expense ratio improvement of 70 bp and raised FY2026 EPS guidance, but operating gain was flat, operating expense rose 9.1% and medical membership fell 1.1%. Overall, the sector shows resilient demand and guidance support alongside rising leverage, litigation and portfolio-reshaping risk.

5 high priority 5 medium 10 total filings
· daily

S&P 500 Technology Sector SEC Filings — October 20, 2026

Three filings were reviewed for the USA S&P 500 Technology stream, all dated 2026-10-20. Two are new since the last brief: an insider sale at Micron Technology (MU) and a Qualcomm (QCOM) CFO/COO Rule 10b5-1 sale, both negative in sentiment. The Salesforce (CRM) 8-K is the most material item (8/10), disclosing a definitive agreement to acquire Braze, Inc. via a joint press release and investor webinar furnished under Item 7.01. The enriched period-over-period, forward-looking, capital allocation, and financial ratio fields are not populated in these filings, so portfolio-level YoY/QoQ trend analysis cannot be quantified from this data set. The dominant theme is insider selling by senior technology executives, executed under 10b5-1 plans and therefore not necessarily signaling a change in management conviction. The Salesforce transaction is the key item to monitor, since the purchase price, structure, and timing sit in exhibits not yet analyzed.

2 high priority 1 medium 3 total filings
· daily

Nasdaq 100 Stocks SEC Filings — October 20, 2026

Across the six filings, the dominant theme is strong top-line momentum masking margin and guidance pressure. Intuitive Surgical posted 22% YoY revenue growth to $3.05B with da Vinci placements rising to 546 from 427, yet GAAP net income fell 26% to $523M after a $450M antitrust settlement charge, and the $22M tariff refund flatters both GAAP and non-GAAP results. Netflix delivered 12% revenue growth and expanded Q3 operating margin to 34.6% from 28.2%, but guided Q4 operating margin sharply lower to 26.0%, cut 2026 ad revenue expectations to ~$2.7B from ~$3B, and lowered 2026 FCF guidance to ~$12.0B from $12.5B. Underneath Netflix's headline growth, EMEA F/X-neutral growth slowed to 9% from 15% and LATAM F/X-neutral growth slowed to 12% from 20%, so reported figures overstate underlying momentum. Insider activity was one-directional in the semiconductor and software names: Micron's President and CTO sold roughly $25.6M of stock at $900 and Qualcomm's CFO/COO sold shares, both under Rule 10b5-1 plans, which reduces the signal value of these sales. The two Strategy Inc DEFA14A filings contain only boilerplate and are immaterial on their own, and the portfolio-level message is that revenue durability is intact while margin trajectory and forward guidance are the key differentiators for the coming quarter.

3 high priority 3 medium 6 total filings
· daily

S&P 500 Financials Sector SEC Filings — October 20, 2026

Seven S&P 500 Financials filings were reviewed for the 2026-10-20 window, though the enriched period-over-period, forward-looking, and capital-allocation fields are populated for only a few of them. The dominant development is Capital One's Q3 2026 print: GAAP EPS of $5.61 rose from $4.73 QoQ and $4.83 YoY, and pre-provision earnings grew 10% QoQ to $7.5B, but deposits fell 1% QoQ to $480.7B and the interest-bearing deposit rate rose 3 bps to 2.94%, so margin gains are being partly consumed by funding costs. Chubb's Q3 shows a mixed picture with record nine-month net income ($8.02B, up 12.9%) and core operating income ($8.60B, up 21.0%), yet North America Commercial deteriorated sharply, with its combined ratio rising to 86.3% from 81.5% and core operating ROTE falling to 21.6% from 24.8%. Underwriting profitability pressure in commercial P&C is therefore the key sector-level tension, while banks are benefiting from reserve releases and steady issuance activity. JPMorgan's $7.0B of debt issuance and Northern Trust's board addition are routine or governance-oriented, carrying limited direct market impact. Insider activity is limited to a tax-withholding event at Northern Trust and a zero-holding filing at Truist, so there is no strong conviction signal from management this cycle.

3 high priority 4 medium 7 total filings
· daily

S&P 500 Energy Sector SEC Filings — October 20, 2026

Two filings were received for the USA S&P 500 Energy stream dated 2026-10-20. Halliburton (HAL) reported a mixed Q3 2026: adjusted net income rose to $501M ($0.60/sh) from $461M ($0.55/sh) and adjusted operating income climbed to $731M from $683M (12.8% adjusted margin), yet GAAP net income fell to $417M ($0.50/sh) from $534M and GAAP operating income dropped 19.8% sequentially to $624M, with revenue flat at $5.7B. The gap is largely explained by $107M of pre-tax impairments and other charges, and free cash flow of $156M lagged operating cash flow of $368M due to capital spending. Management guided to mid-single-digit revenue growth and roughly 15% operating margins for 2027, which is the key forward-looking data point for the name. The second filing, a Form 4 from Kinder Morgan (KMI), is a small, 10b5-1-planned sale by a products-pipelines VP (about $52K, 47,313 shares retained) and carries limited signal on its own. Portfolio-level read: earnings quality at HAL is bifurcated between adjusted improvement and GAAP deterioration, so investors should focus on cash conversion and the 2027 margin trajectory.

1 high priority 1 medium 2 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — October 20, 2026

Three filings are in scope for this Consumer Staples digest, dated October 20, 2026: Kimberly-Clark's $4.9 billion senior notes offering tied to the pending Kenvue acquisition, a Kroger Regulation FD furnishing whose substantive content sits in an unprovided Exhibit 99.1, and a McCormick Form 4 reporting a small phantom stock award to its Chairman, President & CEO. The dominant development is Kimberly-Clark's leverage-funded deal, which introduces a 101% special mandatory redemption backstop and a Q4 2026 closing target that puts balance sheet execution and Kenvue exchange-offer completion squarely in focus. The Kroger filing offers no quantitative period-over-period data, so comparative trend analysis is limited to the Kimberly-Clark financing structure and the modest McCormick insider signal. Because the provided enriched fields for period comparisons, margins, and guidance are largely absent for these filings, conclusions about sector-wide margin or growth trends cannot be drawn from this batch and should be treated as provisional. The actionable takeaways are the Kimberly-Clark deal timeline, the Kroger Exhibit 99.1 review, and monitoring of Kenvue exchange-offer results.

1 high priority 2 medium 3 total filings
· daily

S&P 500 Industrials Sector SEC Filings — October 20, 2026

Across the 17 filings, the industrials complex delivered strong top-line momentum but uneven quality of earnings. GE Aerospace (orders +49%, adjusted revenue +18%, FY26 adjusted EPS guide raised to $8.00-$8.10) and RTX (sales +11%, adjusted EPS +33%, guidance raised) led on growth, while Northrop Grumman (sales +6.7%, backlog $109.6B, book-to-bill 1.5x) showed durable defense demand despite margin compression to 11.4% operating margin. A recurring theme is that headline EPS growth was flattered by non-operating or one-time items: RTX's adjusted EPS included $0.25 of IEEPA recovery, 3M's GAAP EPS gain of 70% rested on a $0.60 Solventum stake gain, and GE's Corporate & Other costs widened to $(511)M from $(279)M on a $(210)M insurance loss. Cash conversion weakened sharply at RTX (operating cash flow -38%, free cash flow -47%) and GE Aerospace (free cash flow and operating cash flow each -14%) even as guidance was lifted. 3M's organic growth was only 0.2% with China sales down 7.3%, and Corporate revenue fell 67.6%. Insider activity across the Union Pacific and Uber filings was routine compensation-related withholding and awards, with no clear directional conviction signal. Overall, the sector is supported by strong order books and defense/aerospace demand, but investors should discount headline EPS and scrutinize cash generation.

14 high priority 3 medium 17 total filings
· daily

Dow Jones 30 Stocks SEC Filings — October 20, 2026

Three of the four filings are in scope and point to a mixed picture for Dow 30 constituents on 2026-10-20. 3M's Q3 2026 results show headline GAAP EPS up 70% to $2.63, but that was inflated by a $0.60 Solventum stake gain versus $0.13 a year earlier; underlying adjusted EPS grew 12% to $2.50 on a new non-GAAP basis that excludes intangible amortization, while GAAP net sales rose only 1.0% and organic sales just 0.2%. Growth quality is weak: China sales fell 7.4% YoY, Corporate revenue collapsed 67.6% to $96 million, and SG&A rose 12.3%, while Fire Safety/Rescue (+90.7%) and Electrical Markets (+13.4%) carried the top line. Management nonetheless raised full-year adjusted EPS guidance to $9.10–$9.15, which investors should weigh against the flat organic trend and the change in non-GAAP definitions. Salesforce's agreement to acquire Braze is the most material corporate-action development, though price, structure and timing sit in unfiled exhibits, so the valuation impact cannot yet be assessed. JPMorgan's $7.0 billion of notes issued under an effective S-3 is routine financing with no change to results or guidance, and the filing reports no period-over-period financial data or insider activity, so it contributes little signal.

1 high priority 3 medium 4 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — October 20, 2026

Across six filings dated October 20, 2026, the consumer discretionary picture is one of strong shareholder returns at General Motors offset by weakening credit quality and cash generation at its captive finance arm, GM Financial. GM Co. reported Q3 revenue of $50.0B (+2.9% YoY), net income attributable to stockholders of $3.3B (vs $1.3B), and narrowed full-year EBIT-adjusted guidance to $14.5B-$15.5B, while completing a $6.0B buyback and authorizing a new $20.0B repurchase program. Nine-month operating cash flow, however, fell 17.2% to $16.6B despite higher reported earnings, and nine-month dividends roughly tripled to $1.05B, a combination that warrants scrutiny of earnings quality. GM Financial's Q3 net income fell 17% to $487M, with provisions for loan losses up 39% to $340M, net charge-offs rising to 1.6% from 1.2%, and operating expenses up 18%, partially masked by a 5.6% decline in interest expense. The leasing book is contracting sharply (nine-month operating lease originations down about 22%), while retail originations held roughly flat, signaling a deliberate shift in mix. Management actions on the non-operational side were routine: Hilton's voluntary NYSE-to-Nasdaq transfer (effective November 5, 2026) and TJX's pre-planned retirement of an SEVP are low-materiality. Overall, the sector narrative is capital return versus credit normalization.

4 high priority 2 medium 6 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — October 20, 2026

Six SEC filings dated 2026-10-20 were reviewed for the USA S&P 500 Healthcare stream. Vertex Pharmaceuticals (board appointment), Intuitive Surgical (Q3 2026 results), and Eli Lilly (four director Form 4 share awards) all sit within the healthcare index scope and were analyzed. The dominant development is Intuitive Surgical's Q3 2026 print: revenue rose 22% YoY to $3.05B and da Vinci placements climbed to 546 from 427, yet GAAP net income fell roughly 27% to $523M after a $450M antitrust settlement charge, and GAAP operating income declined to $593M from $760M. Non-GAAP EPS of $3.00 (vs $2.40) and FY2026 da Vinci procedure guidance of 14%-15% anchor the constructive read, but the $22M tariff refund benefit flatters the quarter and should be stripped out when judging run-rate margins. The Eli Lilly filings are routine, small director equity awards at a uniform $1,240.34 price, signaling board compensation mechanics rather than management conviction. Vertex's appointment of a former Boston Scientific CFO to the board and audit committee is a governance enhancement with neutral near-term market impact. Across the group, the picture is one of strong top-line momentum in medtech and pharma, with cost and litigation items driving GAAP noise.

5 high priority 1 medium 6 total filings